Originally published as JCO Early Release 10.1200/JCO.2005.02.9355 on October 17 2005
Journal of Clinical Oncology, Vol 23, No 33 (November 20), 2005: pp. 8477-8482
© 2005 American Society of Clinical Oncology.
Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy
Soon-Thye Lim,
Roksana Karim,
Anil Tulpule,
Bharat N. Nathwani,
Alexandra M. Levine
From the Division of Hematology, Department of Medicine; Division of Biostatistics, Department of Preventative Medicine; and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA; Department of Medical Oncology, National Cancer Center, Singapore, Singapore
Address reprint requests to Alexandra M. Levine, MD, University of Southern California, 1441 Eastlake Ave, Los Angeles, CA 90033; e-mail: alevine{at}usc.edu
PURPOSE: To compare the prognostic factors for survival and the validity of the International Prognostic Index (IPI) in patients with HIV-related diffuse large-cell lymphoma (HIV-DLCL) treated with curative intent in the prehighly active antiretroviral therapy (HAART) era versus the HAART era.
PATIENTS AND METHODS: We retrospectively reviewed 192 patients with HIV-DLCL diagnosed from 1982 to 2003. Pre-HAART era included 120 patients who did not receive HAART, whereas the HAART era included 72 patients diagnosed after January 1997 who received HAART.
RESULTS: There were no statistically significant differences in terms of either lymphoma or HIV-related characteristics in the two time periods. The complete response rate improved from 32% in the pre-HAART to 57% in the HAART era (P = .0006), and median survival time improved from 8.3 to 43.2 months (P = .0005). In groups with low-, low-intermediate, and high-intermediaterisk IPI disease, 3-year overall survival rates were 20%, 22%, and 5% in the pre-HAART era and 64%, 64%, and 50% in the HAART era, respectively. On multivariate analysis, factors independently associated with decreased survival in both periods were increasing IPI scores and failure to attain complete remission, whereas CD4 less than 100 cells/µL predicted shorter survival in only the pre-HAART era.
CONCLUSION: Prognostic factors and overall survival of patients with HIV-DLCC have changed. Clinical outcomes in patients with HIV-DLCL are now approaching the outcomes of patients with de novo lymphoma.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. E. Stone, B. C. Bounds, V. V. Muse, and J. A. Ferry
Case 29-2009 -- An 81-Year-Old Man with Weight Loss, Odynophagia, and Failure to Thrive
N. Engl. J. Med.,
September 17, 2009;
361(12):
1189 - 1198.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Re, M. Michieli, S. Casari, B. Allione, C. Cattaneo, M. Rupolo, M. Spina, R. Manuele, E. Vaccher, M. Mazzucato, et al.
High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors
Blood,
August 13, 2009;
114(7):
1306 - 1313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-B. Chen, H. Yu, A. Gillani, and J. R. Brown
AIDS-Associated Plasmablastic Lymphoma Presenting at the Insertion Site of a Peritoneal Dialysis Catheter
J. Clin. Oncol.,
July 20, 2007;
25(21):
3176 - 3178.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Straus
Simplified prognostic indicators for AIDS-related lymphoma
Blood,
May 15, 2006;
107(10):
3819 - 3820.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al.
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy
Blood,
May 15, 2006;
107(10):
3832 - 3840.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|